Outcome of inter-hospital transfer of patients on extracorporeal membrane oxygenation in Switzerland by Wilhelm, Markus J et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Outcome of inter-hospital transfer of patients on extracorporeal membrane
oxygenation in Switzerland
Wilhelm, Markus J; Inderbitzin, Devdas Thomas; Reser, Diana; Halbe, Maximilian; Van Tillburg,
Koen; Albrecht, Roland; Müller, Stefan M; Wenger, Urs; Maggiorini, Marco; Rudiger, Alain; Bettex,
Dominique; Schüpbach, Reto; Weber, Alberto; Benussi, Stefano; Von Segesser, Ludwig K; Flammer,
Andreas J; Maisano, Francesco; Ruschitzka, Frank
Abstract: AIMS OF THE STUDY An extracorporeal membrane oxygenation system (ECMO), as a
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only lifesaving option for critically ill patients suffering from refractory cardiac, respiratory or combined
cardiopulmonary failure. As peripheral hospitals may not offer ECMO treatment, tertiary care centres
provide specialised ECMO teams for on-site implantation and subsequent patient transfer on ECMO to
the tertiary hospital. This study reports the results of the largest ECMO transportation programme
in Switzerland and describes its feasibility and safety. METHODS Patients transported on ECMO by
our mobile ECMO team to our tertiary centre between 1 September 2009 and 31 December, 2016 un-
derwent retrospective analysis. Implantation was performed by our specialised ECMO team (primary
transport) or by the medical staff of the referring hospital (secondary transport) with subsequent transfer
to our institution. Type of ECMO, transport data, patient baseline characteristics, operative variables
and postoperative outcomes including complications and mortality were collected from medical records.
RESULTS Fifty-eight patients were included (three patients excluded: one repatriation, two with incom-
plete medical records). Thirty-five patients (60%) received veno-venous, 22 (38%) veno-arterial and one
patient (2%) veno-venoarterial ECMO. Forty-nine (84%) patients underwent primary and nine (16%)
secondary transport. Thirty-five (60%) patients were transferred by helicopter and 23 (40%) by am-
bulance, with median distances of 38.1 (13ndash;225) km and 21 (3-71) km respectively. No clinical
or technical complications occurred during transportation. During hospitalisation, three patients had
ECMO-associated complications (two compartment syndrome of lower limb, one haemothorax after cen-
tral ECMO upgrade). Median days on ECMO was 8 (lt;1ndash;49) and median days in hospital was 17
(lt;1ndash;122). ECMO weaning was successful in 41 patients (71%), on-transport survival was 100%,
40 patients survived to discharge (69%), and overall survival was 67% (39 patients) at a median follow-
up of 58 days (lt;1ndash;1441). Cumulative survival was significantly affected by cardiogenic shock vs.
ARDS (p = 0.001), veno-arterial and veno-venoarterial vs. veno-venous ECMO (p = 0.001) and after
secondary vs. primary transport (p lt;0.001). The ECMO weaning rate was significantly lower after
secondary transfer (22%, two patients, both vaECMO) vs. primary transfer (80%, p = 0.002, 39 patients
of which 35 (71%) had vvECMO). CONCLUSIONS The first results of our ECMO transportation pro-
gramme show its feasibility, safety and efficacy without on-site implant or on-transport complications or
mortality. The favourable early survival may justify the large effort with respect to logistics, costs and
manpower. With rising awareness, referring centres may increasingly consider this lifesaving option at
an early stage, which may further improve outcomes.
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Summary
AIMS OF THE STUDY: An extracorporeal membrane oxy-
genation system (ECMO), as a bridge to either recovery,
a ventricular assist device (VAD), or heart or lung trans-
plantation, may be the only lifesaving option for critically
ill patients suffering from refractory cardiac, respiratory or
combined cardiopulmonary failure. As peripheral hospitals
may not offer ECMO treatment, tertiary care centres pro-
vide specialised ECMO teams for on-site implantation and
subsequent patient transfer on ECMO to the tertiary hos-
pital. This study reports the results of the largest ECMO
transportation programme in Switzerland and describes its
feasibility and safety.
METHODS: Patients transported on ECMO by our mobile
ECMO team to our tertiary centre between 1 September
2009 and 31 December, 2016 underwent retrospective
analysis. Implantation was performed by our specialised
ECMO team (primary transport) or by the medical staff
of the referring hospital (secondary transport) with subse-
quent transfer to our institution. Type of ECMO, transport
data, patient baseline characteristics, operative variables
and postoperative outcomes including complications and
mortality were collected from medical records.
RESULTS: Fifty-eight patients were included (three pa-
tients excluded: one repatriation, two with incomplete
medical records). Thirty-five patients (60%) received
veno-venous, 22 (38%) veno-arterial and one patient (2%)
veno-venoarterial ECMO. Forty-nine (84%) patients un-
derwent primary and nine (16%) secondary transport.
Thirty-five (60%) patients were transferred by helicopter
and 23 (40%) by ambulance, with median distances of
38.1 (13–225) km and 21 (3-71) km respectively. No clini-
cal or technical complications occurred during transporta-
tion. During hospitalisation, three patients had ECMO-as-
sociated complications (two compartment syndrome of
lower limb, one haemothorax after central ECMO up-
grade). Median days on ECMO was 8 (<1–49) and median
days in hospital was 17 (<1–122). ECMO weaning was
successful in 41 patients (71%), on-transport survival was
100%, 40 patients survived to discharge (69%), and over-
all survival was 67% (39 patients) at a median follow-up
of 58 days (<1–1441). Cumulative survival was significant-
ly affected by cardiogenic shock vs. ARDS (p = 0.001),
veno-arterial and veno-venoarterial vs. veno-venous EC-
MO (p = 0.001) and after secondary vs. primary transport
(p <0.001). The ECMO weaning rate was significantly low-
er after secondary transfer (22%, two patients, both vaEC-
MO) vs. primary transfer (80%, p = 0.002, 39 patients of
which 35 (71%) had vvECMO).
CONCLUSIONS: The first results of our ECMO trans-
portation programme show its feasibility, safety and effi-
cacy without on-site implant or on-transport complications
or mortality. The favourable early survival may justify the
large effort with respect to logistics, costs and manpower.
With rising awareness, referring centres may increasing-
ly consider this lifesaving option at an early stage, which
may further improve outcomes.
Keywords: extracorporeal membrane oxygenation, inter-
hospital transportation
Introduction
Extracorporeal membrane oxygenator support for car-
diopulmonary failure was first described by Bartlett and
colleagues in 1977 and has emerged as a lifesaving option
in isolated or combined refractory respiratory and cardiac
failure [1–4]. In patients in whom conventional ventilatory
and haemodynamic support does not allow for safe transfer
to a tertiary care centre, extracorporeal membrane oxy-
genation (ECMO) is an option for cardiopulmonary sta-
bilisation [5–9]. Since ECMO implantation requires par-
ticular expertise and technical equipment that might not
be available in primary medical institutions, highly spe-
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cialised ECMO teams can offer on-site ECMO implanta-
tion at the referring hospital, with subsequent patient trans-
port to their tertiary care centre base [1–3, 10, 11].
Since Bartlett’s description, the concept has developed fur-
ther, mainly in paediatric patients [12, 13]. It became of
major interest in adults during the H1N1 pandemic in
2009/2010, which had a high incidence of acute respiratory
distress syndrome (ARDS) due to pneumonia [14, 15].
Meanwhile, larger studies and reviews have shown the
safety and efficacy of patient transfers on ECMO, with
a negligible on-transport mortality of up to 0.5% and an
overall survival until hospital discharge of >50% [1, 3, 10,
11].
The largest studies, of over 100 transportations of patients
on ECMO, were published by the University of Michigan
(Ann Arbor), University of Arkansas for Medical Sciences
College of Medicine (Little Rock), the Columbia Universi-
ty Medical Center (New York) and Karolinska University
Hospital (Stockholm) [2, 10, 11, 16]. These studies de-
scribe the safety of their transportation on ECMO without
any on-transport mortality and with an overall survival rate
of 60–70%. These outcomes are comparable to the survival
of patients with in-hospital ECMO implantation and to the
results published by the Extracorporeal Life Support Or-
ganization (ELSO, Ann Arbor, MI, USA, www.elso.org)
which has over 400 member-units worldwide and main-
tains a registry on ECMO. Guidelines on ECMO trans-
portation (www.elso.org: “Guidelines for ECMO Trans-
port”) have been published by the ELSO and revised based
on this evidence.
Following these guidelines, the Clinic for Cardiovascular
Surgery at the University Hospital Zurich built up a dedi-
cated ECMO transport team in 2009, the first of its kind in
Switzerland. Since then, it has grown to become the largest
such institution in Switzerland. The objective of this study
is to report on the feasibility, safety and outcomes of pa-
tient transportations on ECMO to our tertiary care centre
by our specialised team from 2009 to 2016.
Materials and methods
Patient cohort and primary endpoint
All patients transported on ECMO by our mobile ECMO
team between September 2009 and December 2016 un-
derwent retrospective analysis. Of the 61 patients identi-
fied, three were excluded. One patient received ECMO in
our hospital and was repatriated to Italy, and two other
patients’ medical records were incomplete. Thus, 58 pa-
tients with ECMO implantation in a peripheral hospital and
subsequent airborne or ground transportation to our cen-
tre were included in this retrospective analysis. The Clin-
ic for Cardiovascular Surgery, together with the Clinic for
Cardiology, constitute the University Heart Centre Zurich,
which offers all treatment modalities for acute and chronic
heart failure. The specialised ECMO team of perfusionists
maintain proper function of all ECMO running in-house
and also provide a perfusionist for the transport of patients
on ECMO, including on-site implantation.
The primary endpoint was overall (implant, on- and post-
transport) survival. Secondary endpoints were overall (im-
plant, on- and post-transport) complications and potential
predictive risk factors identified in a regression analysis.
Protocol: indication and criteria for ECMO implanta-
tion
Intensivists from regional hospitals consult our cardiac sur-
geon on call to request extracorporeal circulation with sub-
sequent transportation to our centre for a critically ill pa-
tient whose condition does not allow conventional
transportation. The patient’s clinical data are discussed by
the ECMO team, which consists of a cardiac surgeon, an
intensivist and a perfusionist. Indications for transportation
on ECMO are potentially reversible cardiac (cardiogenic
shock; CS) or respiratory (acute respiratory distress syn-
drome: ARDS) failure or combined cardiopulmonary fail-
ure which is refractory to conservative intensive care treat-
ment. Detailed diagnoses for CS and ARDS are given in
table 1. Criteria for ECMO generally follow the “Stock-
holm Experience” [2]. The most important respiratory fail-
ure criteria are an oxygen partial pressure <80 mm Hg at
a fraction of inspired oxygen (FiO2) of 100% and respi-
ratory acidosis (pH <7.1). Cardiac failure criteria are aci-
daemia with or without lactataemia, central venous satura-
tion <55% and cardiac index (CI) < 2 l/min/kg bodyweight
despite administration of vasoactive drugs. Contraindica-
tions for ECMO implant are evident irreversibility of CS
or ARDS, irreversible brain injury, intracranial bleeding/
haematoma and other comorbidities with a detrimental
prognosis and a suspected life expectancy <1 year. Howev-
er, the final decision on the indication for ECMO and the
type of ECMO is made by the ECMO team on-site after ar-
rival at the peripheral hospital, together with the local treat-
ment team, based on the patient’s clinical condition.
Type of transport
Two types of patient transfer were defined: primary trans-
fer was defined as an on-site ECMO implantation at the pe-
ripheral hospital by our ECMO team, with subsequent pa-
tient transfer to our tertiary care centre. The transport was
accompanied by a cardiac surgeon, an anaesthesiologist
and a perfusionist. If the ECMO was implanted by a team
from the peripheral hospital prior to the transfer, it was de-
fined as a secondary transfer. In this case, the ECMO team
consisted of an anaesthesiologist and a perfusionist, with-
out a cardiac surgeon. All ECMO systems were implant-
ed and initiated at the peripheral intensive care unit (ICU),
and the patient was stabilised for 30 minutes on ECMO
prior to transportation.
ECMO type, materials and equipment, implantation
In primary transports, the ECMO implantation was a col-
laboration between our ECMO team and an on-site team of
intensivists, nurses, scrub nurses and a cardiologist provid-
ing transoesophageal echocardiography (TEE).
The required equipment, including cannulas, wires, tubing,
sutures, draping and surgical instruments, was provided by
our ECMO team. Both veno-venous (vv) and veno-arte-
rial (va) ECMOs were implanted. In one case, an addi-
tional afferent cannula was implanted in the right internal
jugular vein (JV), resulting in a veno-venoarterial ECMO
circuit. This case was assigned to the vaECMO group
for analysis. The systems used were LiveBox (Sorin, Li-
vaNova SA, Lausanne, Switzerland) until 2015 and there-
after CardiohelpTM (Maquet Inc., Rastatt, Germany). The
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CardiohelpTM all-inclusive kit consists of the oxygenator,
which includes the centrifugal pump. The HLS cannula by
Maquet (Maquet Cardiopulmonary AG, Rastatt, Germany)
was used for venous and arterial cannulas, sized 15 to 29.
Implantation took place in the ICU with the assistance
of a surgical fellow and/or scrub nurse from the referral
unit. After sterile draping, the ECMO implant was started
following the administration of a heparin bolus (100 IU/
kg). Depending on bodyweight and size, venous drainage
was performed by a long heparin-coated 19, 23, 25 or 29
French (F) cannula (Venous HLS Cannula by Maquet Car-
diopulmonary AG, Rastatt, Germany). The cannula was
placed percutaneously via the right femoral vein (VFC)
through the right atrium, with its tip in the superior vena
cava (SVC) in the case of vaECMO, and in the inferior ve-
na cava (IVC), just below its inflow into the right atrium, in
the case of vvECMO. The venous cannulas were implant-
ed under TEE guidance by a local cardiologist using the
bicaval view or alternatively, by fluoroscopy. For afferent
access of vvECMO, the right internal JV was punctured
and a heparin coated 15, 17 or 19 French arterial cannula
(Arterial HLS Cannula by Maquet Cardiopulmonary AG,
Rastatt, Germany) was advanced so that its tip was locat-
ed at the SVC-right atrial (RA) junction. Afferent access
of vaECMO was achieved by percutaneous implantation
of a heparin-coated 15, 17 or 19 F cannula (Arterial HLS
Cannula by Maquet Cardiopulmonary AG, Rastatt, Ger-
many) into the common femoral artery (CFA) or into the
right subclavian artery (RSA) by a surgical cut down. The
arterial femoral access was pre-closed using a ProGlide
Perclose Vascular Closure Device (Abbott Vascular, Al-
tishofen, Switzerland). Prior to insertion of the femoral
cannula, a 7–9 F introducer sheath was percutaneously in-
serted into the superficial femoral artery (AFS) for pe-
ripheral arterial limb perfusion. Adequate arterial puncture
was verified by TEE or fluoroscopic visualisation of the
guide wire in the descending aorta. Trans-cutaneous du-
plex sonography was available to visualise inguinal vessels
and to facilitate the access. In challenging cases, both su-
per-stiff guide wires and head-hunter catheters were used
for the safe placement of the efferent venous cannula. Can-
nulas were securely fixed to the skin by multiple sutures
for safe transportation. The cannulas were flushed and con-
nected to the ECMO device under de-airing. The ECMO
then was initiated.
Means of transportation
Means of transportation included a conventional ground
ambulance and a helicopter (REGA, Rettungsflugwacht,
Switzerland). The choice of appropriate means of transfer
is based on the distance to the referring unit and the weath-
er conditions, which occasionally make a helicopter flight
impossible due to restricted vision. Both helicopter and
ambulance were equipped with a custom-made fixation
plate for the ECMO device to avoid dislocation during
transfer, and the ECMO was connected to the electrical
power of the transport vehicle or helicopter to avoid bat-
tery exhaustion. The anaesthesiologist confirmed car-
diopulmonary stability and stable blood gas analysis prior
to departure and managed ventilator settings and vasoac-
tive drug administration during transportation, while the
perfusionist controlled the ECMO.
Table 1: Demographic data of study population.
Total number of patients (n) 58
Age (years; mean ± SD) 49.3 ± 13.2
Male gender (n; %) 34 (58.6%)
Body weight (kg; mean ± SD) 81.8 ± 23.2
Height (cm; mean ± SD) 170.5 ± 9
Body mass index (kg/m2; mean ± SD) 28.1 ± 7.2
Body surface area (m2; mean ± SD) 1.97 ± 0.35
Resuscitation prior to ECMO implantation (n) 2
Isolated cardiogenic shock (n; %): 18 (31%)
‒ Myocardial infarction 8
‒ Myocarditis 2
‒ Dilative cardiomyopathy 2
‒ Unknown aetiology of cardiac failure 6
Isolated respiratory failure (ARDS) (n; %): 36 (62%)
‒ Pneumonia (aspiration, bacterial) 16
‒ Pneumonia (H1N1 virus) 2
‒ Sepsis 8
‒ Near drowning 1
‒ Trauma 1
‒ COPD exacerbation 1
‒ Asthma with respiratory failure 1
‒ Anaphylactic respiratory failure 1
‒ Open tuberculosis 1
‒ Unknown aetiology for respiratory failure 4
Combined cardiopulmonary failure (n; %) 4 (7%)
‒ Recurrent pulmonary embolism 1
‒ Pulmonary embolism and acute right ventricular failure 1
‒ Sepsis with cardiac failure 1
‒ Pneumonia with cardiac failure 1
ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; ECMO = extracorporeal membrane oxygenation; SD = standard deviation
Original article Swiss Med Wkly. 2019;149:20054
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 9
Outcome: complications, ECMO weaning, survival,
destination of ECMO treatment
Clinical and technical complications (during on-site im-
plantation, during transport, post-transport and ECMO-re-
lated) were looked up in the documents of the referring
hospital, the implant and transportation protocol and the
medical records of our hospital. However, it was not al-
ways possible to retrieve medicals records prior to ECMO
implantation and transport from the referring hospitals.
Therefore, risk scores (e.g. APACHE, SAVE) could not
be reliably evaluated for respective subgroup analyses. No
further sub-categorisation of complications was defined.
Needing to change cannulas or an ECMO upgrade was
analysed and listed separately, and not classified as a com-
plication (table 2).
The ECMO weaning rate was retrieved from the medical
records at our hospital (operations notes and postoperative
course). The principal endpoint of overall survival (during
ECMO implant, during transport, post-transport until dis-
charge and up to the documented post-hospital follow-up)
was evaluated.
Days on ECMO was calculated from the dates of ECMO
implantation and explantation or of death. ICU- and in-
hospital-days were retrieved from medical records. The
follow-up was retrieved from available post-discharge, ex-
ternal or in-house follow-up records.
The ECMO destination was grouped as bridge to recovery,
bridge to ventricular assist device or bridge to heart or lung
transplantation.
Data management and statistical analysis
In this retrospective study, data on transports were collect-
ed throughout the duration of the study in a prospective
manner, with post-hoc retrospective analysis by an inde-
pendent statistician using IBM SPSS Statistics (IBM, Ar-
monk, New York, USA). Continuous variables are given
as mean ± standard deviation or median with range. Cat-
egorical variables are listed as numbers and proportions
(%). Data were compared between groups (diagnosis, type
of ECMO, type of transport, means of transport) using a
Mann-Whitney U test, chi square test or Fisher’s exact test
as appropriate. Overall survival was analysed using Ka-
plan-Meier curves and compared between groups using a
log-rank (Mantel Cox) test. Intergroup differences were
considered statistically significant if p <0.05.
Ethical considerations
The study was approved by the local ethical committee
(Kantonale Ethikkommission Zurich, Project number
BASEC No. 2017-00517) in accordance with the princi-
ples of the declaration of Helsinki. All participating inves-
tigators signed a declaration of confidentiality. All authors
have read and agreed to the manuscript as written.
Results
Fifty-eight patients were included in our analysis. The
caseload grew exponentially over the duration of the study
(fig. 1).
Figure 1: Number of patients on extracorporeal membrane oxy-
genation (ECMO) transported by year. The graph shows an in-
crease in the number of ECMO transports over the duration of the
study, with an exponential increase in 2015 and 2016. One patient
was excluded due to international repatriation following ECMO im-
plantation in our institution and two due to incomplete medical
records from the years 2009 and 2010.
Table 2: ECMO implantation and transportation characteristics.
ECMO configuration Veno-arterial (va) 22 (38%), 9 implanted by referral hospital*
Veno-venous (vv) 35 (60%)†
Veno-venoarterial (v-va) 1 (2%)†
Implanted afferent cannula CFA 21
JV 31
CFV 4
RSA 2
Implanted efferent inguinal
cannula (CFV)
Unilateral 57 (98%)
Bilateral 1 (2%)
Type of transportation Primary (ECMO implant by our team) 49 (84%) of which 35 (71%) vv and 14 (29%) va
Secondary (ECMO implant by referring hospital) 9 (16%) of which 9 (100%) va
Means of transportation: Helicopter (airborne transportation) 35 (60%)
Ambulance (ground transportation) 23 (40%)
Transport distance (Km; medi-
an (min, max))
Helicopter 38.1 (13, 225)
Ambulance 21 (3, 71)
Clinical and technical complica-
tions
During implant at referral unit 0
During transport 0
After arrival, ECMO implant related 3‡
ECMO = extracorporeal membrane oxygenation; CFA = arteria fermoralis communis / common femoral artery; JV = jugular vein; CFV = vena femoralis communis / commune
femoral vein; RSA = arteria subclavia dextra / right subclavian artery * Nine patients received a vaECMO from the team of the referring hospital prior to secondary transport. †
No veno-venous or veno-venoarterial ECMOs were implanted by the referring unit. ‡ Three post-arrival complications related to ECMO implantation: 1. Haemothorax due to com-
plicated upgrade of ECMO; 2. Compartment of lower limb due to absence of peripheral perfusion cannula (secondary transport); 3. Bleeding of femoral arterial access needing
revision.
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Demographic baseline data are summarised in table 1. Two
patients were resuscitated prior to ECMO implant. The
majority of patients (62%, 36 patients) suffered from iso-
lated respiratory failure, while 18 patients (31%) were in
isolated cardiogenic shock. In four patients (7%), com-
bined cardiopulmonary failure required vaECMO. In one
patient with isolated cardiogenic shock after hypoxic car-
diac arrest due to a status asthmaticus, a vvECMO was
sufficient due to haemodynamic stabilisation following ad-
equate oxygenation through the ECMO. In two patients
with isolated respiratory failure, a vaECMO was implanted
on-site due to marginal cardiac function in echocardiogra-
phy.
ECMO implant data and transportation characteristics are
shown in table 2. Of 58 ECMO implants, 35 (60%) were
veno-venous, 22 (38%) were veno-arterial and one (2%)
was veno-venoarterial. Primary transfer was provided in
49 (84%) patients and secondary transfer in 9 (16%). Thir-
ty-five patients (60%) were transported by helicopter (me-
dian distance 38.1 km) and 23 patients (40%) by ambu-
lance (median distance 21 km). No clinical or technical
complications occurred at the referral hospital or during
ECMO transport. After arrival at our hospital, three EC-
MO-related complications were recorded. One patient who
had been transferred with vvECMO after nearly drowning
needed an upgrade to veno-venoarterial ECMO two days
later due to cardiac failure using bilateral inguinal veins
for drainage and both the right subclavian artery and the
right internal jugular vein as afferent vessels. After further
deterioration, a central ECMO had to be implanted. The
patient developed postoperative haemothorax needing sur-
gical revision. The second patient (secondary transfer) de-
veloped a compartment syndrome due to ischaemia of the
lower limb caused by the lack of a peripheral arterial perfu-
sion cannula until arrival in our hospital. The third patient
needed a change of the arterial femoral cannula to the oth-
er inguinal side due to continuous bleeding at the cannula-
tion site. The patient developed a compartment syndrome
on the side of initial cannulation.
No significant difference between the patient groups “type
of ECMO” or “type of transport” were found with refer-
ence to age, gender, bodyweight, body size and body mass
index (table 3).
Differences between patients with vvECMO versus vaEC-
MO and primary versus secondary transport are shown in
tables 4A and 4B. Duration of ECMO therapy (median 8
days (1–49)) and ICU stay (median 13 days (1–101)) were
comparable for both type of ECMO and type of transport.
Hospital stay (median 17 days (1–122)) was also similar
in vvECMO and vaECMO, but significantly longer after
primary transfer than after secondary transport (19 days
(1–122) versus 7 days (1–35), p = 0.048)). Median fol-
low-up after ECMO implant was 58 days (1–1441). This
was significantly longer after vvECMO than after vaEC-
MO, and also significantly longer after primary transport
than after secondary transport (Tables 4A/B). There was no
significant difference between vvECMO and vaECMO re-
garding the need for an ECMO upgrade, but adjustments
of the initial cannulation were significantly more frequent
after vaECMO than after vvECMO (n = 6 (26%) versus n
= 2 (6%), p = 0.048). Weaning from ECMO was possible
in 71% of patients, with a significant difference between
vvECMO (83%) and vaECMO (52%) (p = 0.041). The
weaning rate after primary transfer was 80% compared to
22% after secondary transfer (p = 0.002). Survival during
transport was 100%. Survival to discharge was 69% in the
total cohort. It was 83% in vvECMO compared to 48% in
vaECMO (p = 0.008), and 80% after primary transport ver-
sus 11% after secondary transport (p<0.001). Overall sur-
vival was 67%, with a rate of 83% in vvECMO versus 43%
in vaECMO (p = 0.001) and 78% after primary transfer
versus 11% after secondary transfer (p <0.001). One pa-
tient died after hospital discharge due to cerebral haem-
orrhage on oral anticoagulation, while all other (n = 18)
documented deaths occurred during hospitalisation (mul-
ti-organ failure (n = 13), respiratory failure (n = 2) and
cerebral ischa emia after resuscitation (n = 3)). Complete-
ness of follow-up after hospital discharge was 88% (35 pa-
tients).
Outcomes of ECMO therapy are displayed in table 5. EC-
MO served as a bridge to recovery in 38 (66%) patients and
to a ventricular assist device (VAD) in two (3%) patients.
One of the VAD patients died 25 days after discharge due
to cerebral bleeding under oral anticoagulation. Another
patient was bridged to salvage cardiac surgery. After resus-
citation in the peripheral coronary angiography laboratory
and stenting of the right coronary artery, vaECMO was im-
planted, followed by primary transfer to our hospital. Af-
ter emergency mitral valve replacement upon arrival due
to acute mitral regurgitation in ischemic papillary muscle
rupture, the patient died after surgery due to multi-organ
failure.
Kaplan-Meier cumulative survival was mainly affected by
the first days after ECMO transportation, during hospital-
isation (fig. 2A). It was significantly lower in CS than in
ARDS (p = 0.001) fig. 2B), in vaECMO than in vvEC-
MO (p = 0.001) (fig. 2C) and in secondary than in primary
transport (p <0.001) (fig. 2D). However, survival was not
significantly influenced by means of transportation (p =
0.75) (fig. 2E).
Table 3: Demographic data for study groups by type of extracorporeal membrane oxygenation (ECMO) and type of transport.
VV ECMO
n = 35
VA ECMO*
n = 23
p-value Primary transport
n = 49
Secondary transport
n = 9
p-value
Age (years; mean ± SD) 48.5 ± 13 50.6 ± 13 0.62† 48.3 ± 13.6 55.3 ± 9.3 0.27†
Male gender (n; % of group) 19 (54) 15 (65) 0.43‡ 28 (57) 6 (67) 0.72‡
Body weight
(kg; mean ± SD)
78 ± 20 87 ± 26 0.13† 80.7 ± 24.2 87.8 ± 16.7 0.13†
Height (cm; mean ± SD) 170 ± 9 171 ± 7 0.56† 170 ± 9 175 ± 7 0.08†
Body mass index (kg/m2; mean ±
SD)
27.1 ± 5.5 29.6 ± 9 0.28† 28 ± 7.7 28.6 ± 4.2 0.38†
VV = veno-venous; VA = veno-arterial p-value: significant if p <0.05 * Including one case of veno-venoarterial ECMO † Mann-Whitney U test, asymptotic significance two-sided
(significant if p < 0.05) ‡ Fisher’s exact test, exact significance two-sided (significant if p < 0.05)
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Table 4A: Follow-up data by type of extracorporeal membrane oxygenation (ECMO).
Total
n = 58
VV ECMO
n = 35
VA ECMO*
n = 23
p-value
Days on ECMO
(median (min, max))
8 (<1, 49) 7 (<1, 49) 8 (<1, 35) 0.82†
Days on ICU
(median (min, max))
13 (<1, 101) 14, <1, 101) 12 (<1, 41) 0.15†
Days in hospital
(median (min, max))
17 (<1, 122) 24 (<1, 115) 15 (<1, 122) 0.15†
Days of follow-up
(median (min, max))
58 (<1, 1441) 127 (<1, 1441) 19 (<1, 790) 0.01†
Upgrading of ECMO
(n; % of group)
9 (16) 5 (14) 4 (17) 1.0‡
Cannula change ECMO
(n; % of group)
8 (14) 2 (6) 6 (26) 0.048‡
Weaning from ECMO
(n; % of group)
41 (71) 29 (83) 12 (52) 0.041‡
Survival during transport
(n; % of group)
58 (100) 35 (100) 23 (100) –
Survival to hospital discharge
(n; % of group)
40 (69) 29 (83) 11 (48) 0.008‡
Overall survival
(n; % of group)
39 (67) 29 (83) 10 (43) 0.001‡
Values <1 indicate a time-span of less than 24 hours. * Including one case of veno-venoarterial ECMO † Mann-Whitney U test, asymptotic significance two-sided (significant if p
<0.05) ‡ Fisher’s exact test, exact significance two-sided (significant if p <0.05)
Table 4B: Follow-up data by type of transport.
Total
n = 58
Primary transport
n = 49
Secondary transport
n = 9
p-value
Days on ECMO
(median (min, max))
8 (<1, 49) 8 (<1, 49) 7 (1, 35) 0.54*
Days on ICU
(median (min, max))
13 (<1, 101) 15 (<1, 101) 7 (1, 35) 0.1*
Days in hospital
(median (min, max))
17 (<1, 122) 19 (<1, 122) 7 (1, 35) 0.048*
Days of follow-up
(median (min, max))
58 (<1, 1441) 79 (<1, 1441) 7 (1, 790) 0.01*
Upgrading of ECMO
(n; % of group)
9 (16) 8 (16) 1 (11) 1.0†
Cannula change ECMO
(n; % of group)
8 (14) 6 (12) 2 (22) 0.6†
Weaning from ECMO
(n; % of group)
41 (71) 39 (80) 2 (22) 0.002†
Survival during transport
(n; % of group)
58 (100) 49 (100) 9 (100) –
Survival to hospital discharge
(n; % of group)
40 (69) 39 (80) 1 (11) <0.001†
Overall survival
(n; % of group)
39 (67) 38 (78) 1 (11) <0.001†
Values <1 indicate a time-span of less than 24 hours. * Mann-Whitney U test, asymptotic significance two-sided (significant if p <0.05) † Fisher’s exact test, exact significance
two-sided (significant if p <0.05)
Table 5: Outcomes of ECMO treatment in all patients.
Total number of patients (n) 58
Bridge to recovery (n; %) 38 (66%)
Bridge to ventricular assist device (n; %)* 2 (3%)
Bridge to salvage surgery (n; %)† 1 (2%)
Death‡ (n; %) 17 (29%)
* One patient died 25 days after discharge with a ventricular assist device due to cerebral haemorrhage under oral anticoagulation. † After resuscitation in a peripheral coronary
angiography laboratory and emergency stenting of the right coronary artery, vaECMO was implanted by our ECMO team with primary transfer to our hospital followed by emer-
gency mitral valve replacement for acute mitral regurgitation due to ischemic papillary muscle rupture. The patient died of subsequent multi-organ failure. ‡ These 17 patients
died prior to any decision on a potential bridge to another post-ECMO-treatment (e.g., LVAD, transplant, surgery). The overall mortality of 19 patients includes two more patients
who received an LVAD and salvage surgery.
Discussion
The principle of transporting critically ill patients to a ter-
tiary care centre with a highly specialised intensive care
unit and a broad experience in ECMO treatment has been
recently demonstrated to reduce mortality [2, 3, 10, 11,
16, 17]. The transfer of a haemodynamically or respira-
torily unstable patient without extracorporeal circulatory
support may be an incalculable risk. It can be reduced
by ECMO implementation on-site at the referring hospital
and subsequent patient transport on ECMO. Several au-
thors have reported a very low on-transport mortality of
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Figure 2A: Kaplan-Meier curves for overall cumulative survival
curve (n = 58).
Figure 2B: Kaplan-Meier cumulative survival curves grouped by
diagnosis: blue graph cardiogenic shock (CS, n = 22) and green
graph acute respiratory distress syndrome (ARDS, n = 36). Four
patients with combined cardiopulmonary failure were assigned to
the CS group. Log-rank (Mantel Cox) test: p = 0.001.
Figure 2C: Kaplan-Meier cumulative survival curves grouped by
type of extracorporeal membrane oxygenation (ECMO): green
graph veno-venous (VV, n = 35) and blue graph non-veno-venous
= veno-arterial (VA, including one patient on veno-venoarterial EC-
MO, n = 23). Log-rank (Mantel Cox) test: p = 0.001.
patients transported on ECMO, and a similar overall mor-
tality compared to patients receiving an ECMO at the EC-
MO centre. This supports the concept of an ECMO trans-
portation programme [1, 3, 10, 11].
Figure 2D: Kaplan-Meier cumulative survival curves grouped by
type of transport: blue graph primary (n = 49) and green graph
secondary (n = 9) transport. Log-rank (Mantel Cox) test: p <0.001.
Figure 2E: Kaplan-Meier cumulative survival curves grouped by
means of transport: blue graph helicopter (n = 35) and green graph
ambulance (n = 23). Log-rank (Mantel Cox) test: p = 0.75.
Based on the current literature and the data of the inter-
national ECMO registry, the ELSO published “Guidelines
for ECMO Transport” addressing standardised aspects of
medical personnel, equipment, anticoagulation and trans-
port logistics (www.elso.org: “Guidelines for ECMO
Transport”). The organisation of our ECMO transport team
and equipment is in accordance with those recommenda-
tions. For in-centre ECMO implantation, the Internation-
al ECMO Network has recommended a minimum of 20
ECMO implantations per year for acute respiratory failure
[18]. An analysis of the ELSO registry identified a volume
of 30 annual ECMO implantations per centre to be associ-
ated with reduced mortality [19]. However, no such case-
loads have been defined in ECMO transportation so far. In
2016, we have reached numbers of ECMO transportation
which ECMO network and ECMO registry recommend for
in-centre ECMO implantation.
Our overall outcomes reflect a successful implementation
of the ECMO transportation programme at our institution,
with a 100% implant and on-transport survival, a 100%
absence of on-site or on-transport technical and clinical
complications, a 69% survival to discharge rate and a 67%
overall survival rate. These results are in line with the re-
cently published data from larger cohorts and reviews sum-
marising smaller collectives, which describe a survival to
discharge rate of approximately 61–63% for all transport-
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ed ECMO patients (vv and va) [1–3, 10, 11]. This does not
differ much from the survival of ECMO patients without
transfer of 58%, published by the ELSO (www.elso.org:
ECLS Registry Report 2016).
Veno-venous ECMO resulted in a significantly better
weaning rate, survival to discharge rate and overall sur-
vival rate compared to vaECMO. These findings are com-
parable to the literature and reflect the underlying diagno-
sis, with a significantly higher risk in patients with cardiac
or combined failure compared to patients with stand-alone
respiratory failure [1–3, 10, 11]. The higher rate of can-
nulation change in patients on vaECMO compared to pa-
tients on vvECMO is explained by the fact that downgrad-
ing from vaECMO to vvECMO was included, which was
part of the weaning process in some vaECMO patients.
The significantly shorter hospital stay and follow-up of pa-
tients after secondary transfer compared to after primary
transport is because of the low survival to discharge rate in
this group. All secondary transport patients were on vaEC-
MO which, as we have shown, was associated with a less
favourable prognosis and may explain, at least partly, the
poor outcome in this subgroup.
Some deaths prior to transport have been described, but the
exact number of patients that were lost due to the late ar-
rival of the ECMO team are lacking and are most proba-
bly underestimated [1]. Broman et al. identified 13 ECMO
candidates in their own cohort within a period of four years
who died before ECMO was installed, indicating the prob-
lem of delays and the importance of immediate alert by the
referring hospital in the case of haemodynamic or respira-
tory deterioration [1]. This emphasises the utmost impor-
tance of peripheral hospitals contacting the ECMO centre
early.
While some rare cases of death during transport have been
previously described, there were no deaths during implant
or transport in our cohort [1, 3, 10, 11]. The absence of
technical or clinical complications during implant and
transport compares favourably to the data in the literature
[1, 11, 20, 21]. The incidence of on-transport complica-
tions has been reported to be as high as 31.7% [20]. How-
ever, such studies also documented adverse events not di-
rectly related to the patient or the ECMO which might
explain the difference [20, 21]. The most frequently de-
scribed complications are patient-related, such as loss of
tidal volume, followed by staff-related complications and
technical and vehicle malfunctions.
The appropriate choice of ECMO type may prevent fatal
events during transportation. Patients with acute respira-
tory failure and borderline haemodynamic stability should
be considered for straight vaECMO implantation. Broman
et al. cite two cases of patients taken on vvECMO who
died during transport due to acute cardiac failure [2, 11].
Thus, two of our patients with a primarily respiratory fail-
ure were transported on vaECMO upon the decision of the
ECMO team due to an expected risk of on-transport car-
diac deterioration.
A variety of technical equipment and systems have been
tested for feasibility and safety in various studies [21–24].
The miniaturisation of systems has certainly facilitated the
transport of patients on ECMO. Maintenance and constant
updates to the current technical standards must be ap-
proved by the team of perfusionists. Fast and safe trans-
portation is a key factor for success. Both were profession-
ally provided by REGA and “Schutz und Rettung Zürich”
which supplied us with a helicopter and ambulance, re-
spectively. Paramedics from both institutions developed a
custom-made fixation plate for the ECMO together with
the perfusionists to avoid dislocation during transfer.
Percutaneous cannulation at a peripheral institution is a
particular challenge. The cardiac surgeon performing the
procedure is confronted with an unfamiliar environment
and unknown staff to work with, although, in our experi-
ence, the personnel in other hospitals are always very help-
ful. Thus, the implantation can only be successful if the
operator is well trained, equipped with sufficient interven-
tional skills and capable of solving potential problems by
eventual surgical cut-down. The early implant of a periph-
eral perfusion cannula into the femoral artery distally to
the afferent ECMO cannula is crucial to avoid peripheral
limb ischaemia. Due to haemodynamic instability, an im-
plant prior to ECMO cannulation is not always feasible.
After arrival at the tertiary care centre at the latest, a pe-
ripheral perfusion cannula should be installed under duplex
sonography or fluoroscopy.
Conclusions
The first results of the largest ECMO transportation pro-
gramme in Switzerland show its feasibility, safety and ef-
ficacy, without on-site implant or on-transport complica-
tions or mortality. The outcomes of patients on vvECMO
and vaECMO are at least as good as in patients who re-
ceive the ECMO directly in the specialised ECMO centre
without the need for transportation. This may justify the
enormous level of logistics, expenditure and manpower re-
quired. Primary care centres are invited to use the option
of on-site ECMO implantation with subsequent transporta-
tion to a specialised ECMO centre in patients with critical
acute cardiac or respiratory failure. With rising awareness,
referring centres will begin to consider this service at an
early stage when the patient’s condition still leaves all ther-
apeutic options open. Early communication will facilitate
logistic organisation and accelerate the onset of ECMO
treatment.
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